Key points from article :
Videregen gears up for clinical trials of regenerated organs and tissues to cure chronic and immune-related disease.
Its technology can help restore the thymus, potentially rejuvenating our immune system in the process.
Researchers discovered novel progenitor cells...to build a better functioning thymus from scratch.
Uses decellularization process to isolate extracellular matrix of a tissue, leaving only a scaffold of the original tissue.
Scaffold can then be seeded with appropriate cells to enable organ and tissue regeneration.
“The technology is predominantly around the identification, isolation and culture of the correct cell types that are able to reconstitute the immune system,” says Steve Bloor, CEO of Videregen.
Approved for initial clinical trials in respiratory disease and is working towards regenerative thymus technology in 3 years.
Initial indication for Videregen’s immune program is children born without thymus function - complete DiGeorge Syndrome.
Videregen is now seeking $10 million to move both of its programs through to clinical trials.
Research by Francis Crick Institute published in Nature.
